SCHEMBL3100377

SCHEMBL3100377

CCCc1nc(N)sc1C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.47
CYP1A2 P05177 1/20 0.47
HPGD P15428 2/20 0.44
FBP1 P09467 1/20 0.43
MAPT P10636 2/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
KDM4E B2RXH2 5/20 0.41
PKM P14618 2/20 0.41
HSD17B10 Q99714 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
HSP90AA1 P07900 1/20 0.39
TSHR P16473 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1540028 0.88 ALDH1A1 (0.49) ALDH1A1CYP1A2HPGDMAPTKMT2A
SCHEMBL2444986 0.86 ALDH1A1 (0.50) ALDH1A1CYP1A2HPGDFBP1MAPT
SCHEMBL2082176 0.85 ALDH1A1 (0.67) ALDH1A1CYP1A2HPGDFBP1MAPT
SCHEMBL741937 0.85 HSD17B10 (0.49) ALDH1A1CYP1A2HPGDMAPTKMT2A
SCHEMBL2444646 0.83 L3MBTL1 (0.46) ALDH1A1CYP1A2HPGDMAPTKMT2A
SCHEMBL5221270 0.81 ALDH1A1 (0.44) ALDH1A1CYP1A2HPGDFBP1MAPT
SCHEMBL31661300 0.77 ALDH1A1 (0.41) ALDH1A1CYP1A2HPGDFBP1MAPT
SCHEMBL1552396 0.77 ALDH1A1 (0.69) ALDH1A1CYP1A2HPGDFBP1MAPT
SCHEMBL2823884 0.76 ALDH1A1 (0.63) ALDH1A1CYP1A2HPGDFBP1MAPT
SCHEMBL3095838 0.75 FBP1 (0.66) ALDH1A1CYP1A2HPGDFBP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106632134-B 2- (4-thiazolinone-2-imino) thiazole-5-carboxylic ester and preparation method and application thereof 湖南大学 2020-01-03 CN disclosed
US-7795289-B2 Use of acylaminothiazole derivatives as therapeutic agents SANOFI-AVENTIS (FR) 2010-09-14 US disclosed
US-20080051436-A1 Use of Acylaminothiazole Derivatives as Therapeutic Agents SANOFI-AVENTIS (FR) 2008-02-28 US disclosed
US-7291636-B2 Acylaminothiazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-11-06 US disclosed
US-20050182104-A1 Acylaminothiazole derivatives, preparation and therapeutic use thereof SANOFI-SYNTHELABO (FR) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051436-A1 Use of Acylaminothiazole Derivatives as Therapeutic Agents BACE1, BACE2, ATG4A ALDH1A1 1460/4885CYP1A2 2175/4885HPGD 2538/4885
US-20050182104-A1 Acylaminothiazole derivatives, preparation and therapeutic use thereof BACE1, APP, BACE2 ALDH1A1 1639/4885CYP1A2 2038/4885HPGD 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.